Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810246 | 0.77 | HSP90AA1 (0.39) | HSP90AA1CYP19A1 | |
| SCHEMBL28476071 | 0.76 | MEN1 (0.45) | — | |
| SCHEMBL2554967 | 0.75 | HSP90AA1 (0.38) | HSP90AA1CYP19A1 | |
| SCHEMBL4185103 | 0.73 | SLC6A2 (0.35) | CYP19A1 | |
| SCHEMBL11842818 | 0.73 | ATM (0.39) | HSP90AA1 | |
| SCHEMBL6471934 | 0.72 | HSP90AA1 (0.40) | HSP90AA1CYP19A1 | |
| SCHEMBL16402794 | 0.72 | HSP90AA1 (0.35) | HSP90AA1CYP19A1 | |
| SCHEMBL15058024 | 0.72 | HSP90AA1 (0.35) | HSP90AA1CYP19A1 | |
| SCHEMBL9970860 | 0.70 | — | — | |
| SCHEMBL16402858 | 0.68 | CYP2D6 (0.35) | HSP90AA1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689395-B1 | VINCA DERIVATIVES | ALBANY MOLECULAR RES INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-8895543-B2 | Vinca derivatives | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7745619-B2 | alkaloids; anticarcinogenic, antiproliferative agent; inhibitor of cellular mitosis and cell proliferation; binding to tubulin leads to cell cycle arrest in M phase and subsequently to apoptosis; antiallergen, antiinflammatory, antidiabetic, autoimmune diseases; asthma, arthritis, Alzheimer' disease | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080108644-A1 | VINCA DERIVATIVES | AMR TECHNOLOGY, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20070179171-A1 | alkaloids; anticarcinogenic, antiproliferative agent; inhibitor of cellular mitosis and cell proliferation; binding to tubulin leads to cell cycle arrest in M phase and subsequently to apoptosis; antiallergen, antiinflammatory, antidiabetic, autoimmune diseases; asthma, arthritis, Alzheimer' disease | AMR TECHNOLOGY, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-7238704-B2 | For use as inhibitors of cellular mitosis and proliferation | AMR TECHNOLOGY, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20050137169-A1 | Vinca derivatives | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2005-06-23 | — | — | US | disclosed |
| US-3995039-A | Pyrazolo [1,5-a] [1,3,5] triazines | MERCK & CO., INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | HSP90AA1 1639/4885CYP19A1 571/4885 |
| US-20070179171-A1 | alkaloids; anticarcinogenic, antiproliferative agent; inhibitor of cellular mitosis and cell proliferation; binding to tubulin leads to cell cycle arrest in M phase and subsequently to apoptosis; antiallergen, antiinflammatory, antidiabetic, autoimmune diseases; asthma, arthritis, Alzheimer' disease | CCNB1, CCNB3, BUB1 | HSP90AA1 747/4885CYP19A1 381/4885 |
| US-20050137169-A1 | Vinca derivatives | UGT1A3, CA5A, VIM | HSP90AA1 2128/4885CYP19A1 118/4885 |
| US-20080108644-A1 | VINCA DERIVATIVES | UGT1A3, CA5A, VIM | HSP90AA1 2128/4885CYP19A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.